You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Discontinued ProductPyroxamide (Cat. No. 4403) has been withdrawn from sale for commercial reasons.
Biological Activity for Pyroxamide
Pyroxamide is an inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.
Technical Data for Pyroxamide
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References for Pyroxamide
References are publications that support the biological activity of the product.
Butler et al (2001) Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase. Clin.Cancer Res. 7 962 PMID: 11309347
Remiszewski et al (2002) Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J.Med.Chem. 45 755 PMID: 11831887
Bradner et al (2010) Chemical phylogenetics of histone deacetylases. Nat.Chem.Biol. 6 238 PMID: 20139990
Carrillo et al (2015) Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT). Bioorg.Med.Chem. 23 5151 PMID: 25637120
View Related Products by Product Action
Keywords: Pyroxamide, Pyroxamide supplier, Pyroxamide, hdac, histone, deacetylase, inhibitors, inhibits, epigenetics, Class, I, HDACs, 4403, Tocris Bioscience
1 Citation for Pyroxamide
Citations are publications that use Tocris products. Selected citations for Pyroxamide include:
Kim (2018) Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Br J Cancer 118 1359 PMID: 29695769
Reviews for Pyroxamide
Average Rating: 5 (Based on 1 Review.)
Have you used Pyroxamide?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
TGF beta high responder treated with 1.5 μM Pyroxamide (HDAC 1 inhibitor) for 48 h. Cell lysates were analysed by western blot.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Cell Cycle & DNA Damage Repair Poster
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. Adapted from the 2015 Cancer Product Guide, Edition 3, this poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
Epigenetics in Cancer Poster
Adapted from the 2015 Cancer Product Guide Edition 3, this poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.
Rheumatoid Arthritis Poster
Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.